|  |
| --- |
| **Additional file 2: Table S2a** **Correlation and conversion of PODXL expression (trichotomized) between paired tissue samples in the neoadjuvant cohort** |
|  | **PODXL in pre-neoadjuvant biopsy** |  | **PODXL in post-neoadjuvant resected** **lymph node metastasis** |
| **PODXL in post-neoadjuvant resected primary tumor** | Negative | Low | High | Correlation (*τ*b)pConversion (any) | **PODXL in post-neoadjuvant resected primary tumor** | Negative | Low | High | Correlation (*τ*b)pConversion (any) |
| Negative | 8 10.8% | 1723.0% | 11.4% | 0.0030.98158.2% | Negative | 12 28.6% | 37.1% | 0 | 0.484**<0.001**30.9% |
| Low | 16 21.6% | 2229.7% | 6 8.1% | Low | 49.5% | 1535.7% | 37.1% |
| High | 22.7% | 11.4% | 11.4% | High | 24.8% | 12.4% | 24.8% |

|  |
| --- |
| **Additional file 2: Table S2b****Correlation and conversion of PODXL expression (dichotomized) between paired tissue samples in the neoadjuvant cohort** |
|  | **PODXL in pre-neoadjuvant biopsy** |  | **PODXL in post-neoadjuvant resected** **lymph node metastasis** |
| **PODXL in post-neoadjuvant resected primary tumor** | Negative | Positive | Correlation (*τ*b)pConversion (any) | **PODXL in post-neoadjuvant resected primary tumor** | Negative | Positive | Correlation (*τ*b)pConversion (any) |
| Negative | 810.8% | 1824.3% | -0.0670.55648.6% | Negative | 1228.6% | 37.1% | 0.559**<0.001**21.4% |
| Positive | 1824.3% | 3040.5% | Positive | 614.3% | 2150.0% |